Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 6/20 | 0.36 |
| ▸ | CNR2 | P34972 | 6/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2618732 | 0.95 | CYP1A2 (0.37) | TP53MAPK1ALOX15CNR1CNR2 | |
| SCHEMBL2618723 | 0.90 | CYP1A2 (0.38) | TP53MAPK1ALOX15CNR1CNR2 | |
| SCHEMBL2619098 | 0.84 | TSHR (0.37) | MAPK1CYP1A2POLBCYP2D6TSHR | |
| SCHEMBL2619024 | 0.84 | TSHR (0.37) | MAPK1CYP1A2POLBCYP2D6TSHR | |
| SCHEMBL14455056 | 0.83 | L3MBTL1 (0.44) | TP53MAPK1ALOX15CNR1CNR2 | |
| SCHEMBL16472477 | 0.79 | PTGS2 (0.32) | KDM4E | |
| SCHEMBL2610731 | 0.78 | HTR1B (0.49) | POLBL3MBTL1KDM4E | |
| SCHEMBL2610783 | 0.77 | NOS3 (0.38) | KCNH2 | |
| SCHEMBL2610786 | 0.75 | NOS3 (0.39) | KCNH2S1PR4 | |
| SCHEMBL1744467 | 0.73 | CA12 (0.55) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163736-B2 | Cytotoxic agents comprising new tomaymycin derivatives | SANOFI-AVENTIS (FR) | 2012-04-24 | — | — | US | disclosed |
| US-20090036431-A1 | Cytotoxic Agents Comprising New Tomaymycin Derivatives | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036431-A1 | Cytotoxic Agents Comprising New Tomaymycin Derivatives | TOMM70, TOMM34, TOMM40 | TP53 122/4885MAPK1 3159/4885ALOX15 4230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.